ABOS
Price:
$2.22
Market Cap:
$133.38M
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.[Read more]
Industry
Biotechnology
IPO Date
2021-07-01
Stock Exchange
NASDAQ
Ticker
ABOS
According to Acumen Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -24.63%. This represents a change of 295.78% compared to the average of -6.22% of the last 4 quarters.
The mean historical ROE of Acumen Pharmaceuticals, Inc. over the last ten years is -2.70%. The current -24.63% ROE has changed 812.48% with respect to the historical average. Over the past ten years (40 quarters), ABOS's ROE was at its highest in in the March 2021 quarter at 59.38%. The ROE was at its lowest in in the March 2020 quarter at -34.20%.
Average
-2.70%
Median
-19.62%
Minimum
-80.68%
Maximum
68.84%
Discovering the peaks and valleys of Acumen Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 68.84%
Minimum Annual Increase = -304.80%
Minimum Annual ROE = -80.68%
Year | ROE | Change |
---|---|---|
2023 | -19.62% | -8.51% |
2022 | -21.44% | -73.43% |
2021 | -80.68% | -304.80% |
2020 | 39.40% | -42.78% |
The current ROE of Acumen Pharmaceuticals, Inc. (ABOS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-40.58%
5-year avg
-2.70%
10-year avg
-2.70%
Acumen Pharmaceuticals, Inc.’s ROE is greater than Terns Pharmaceuticals, Inc. (-39.58%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Mereo BioPharma Group plc (-63.39%),
Company | ROE | Market cap |
---|---|---|
-39.58% | $549.60M | |
32.93% | $109.78M | |
-122.70% | $1.25B | |
-51.77% | $159.50M | |
-46.15% | $161.36M | |
-68.93% | $312.42M | |
-63.39% | $664.26M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Acumen Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Acumen Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Acumen Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Acumen Pharmaceuticals, Inc. (ABOS)?
What is the highest ROE for Acumen Pharmaceuticals, Inc. (ABOS)?
What is the 3-year average ROE for Acumen Pharmaceuticals, Inc. (ABOS)?
What is the 5-year average ROE for Acumen Pharmaceuticals, Inc. (ABOS)?
How does the current ROE for Acumen Pharmaceuticals, Inc. (ABOS) compare to its historical average?